Cytek Biosciences (CTKB) Q1 2026 earnings review
Top-Line Resilience Overshadowed by Profitability Collapse
Cytek Biosciences delivered a stabilizing 6% YoY revenue growth in Q1 2026, driven by a resilient 15% increase in service revenue. However, the top-line beat is completely overshadowed by a severe deterioration in profitability. Net loss widened to $18.9M as G&A expenses surged 43% YoY. Management blamed this spike on litigation, outside consulting, and notably, bad debt reserves—a red flag pointing to potential customer distress. While the company reaffirmed its modest 2-5% full-year growth guidance, the expanding adjusted EBITDA loss of $9.1M presents a stark contrast to the growth narrative.
🐂 Bull Case
Service revenue grew a robust 15% YoY to $15.4M. The installed base expanded by 125 units to 3,789, cementing a recurring revenue stream (services + reagents) that now represents 35% of trailing-12-month total revenue, up from 31% a year ago.
Despite a challenging capital equipment spending environment, total revenue remained in positive growth territory (+6% YoY), proving that the core FSP platform continues to capture market share.
🐻 Bear Case
G&A expenses skyrocketed 43% YoY to $18.5M. The explicit mention of 'bad debt reserves' alongside litigation costs suggests underlying friction in collections and operational efficiency.
Adjusted gross margin decelerated to 51% (from 52% in 25Q1), and adjusted EBITDA loss widened severely to $9.1M. The company is burning profitability to sustain low-single-digit revenue growth.
⚖️ Verdict: 🔴
Bearish. While management highlights installed base growth and top-line resilience, the aggressive spike in G&A, expanding operational losses, and the emergence of bad debt reserves suggest poor earnings quality and execution risks ahead.
Key Themes
Litigation and Bad Debt Crush Margins
The most alarming data point in the Q1 print is the 43% YoY explosion in G&A expenses to $18.5M. Management attributed this accelerating trend to litigation-related expenses, outside consulting, and bad debt reserves. The inclusion of bad debt implies customers are struggling to pay, a potential leading indicator of deeper macro weakness affecting their client base. This completely reversed the improving profitability trend seen in the second half of 2025.
Recurring Revenue Provides a Durable Anchor
Cytek's strategic shift toward a more predictable business model is working. Total recurring revenue (service and reagents) reached $18.4M in Q1. On a trailing-12-month basis, this segment now accounts for 35% of total revenue, reflecting stable, compounding growth compared to 31% in Q1 2025. Service revenue alone grew 15% YoY, far outpacing the sluggish 2.4% product revenue growth.
Installed Base Expansion Despite Macro Headwinds
The company added 125 units in Q1, bringing the total installed base to 3,789 Cytek instruments. While instrument placements are subject to capital budget volatility, each new placement directly feeds the high-margin recurring revenue engine. This steady volume growth demonstrates the continued adoption of their Full Spectrum Profiling (FSP) technology.
Gross Margin Compression Continues
Profitability at the unit level is decelerating. GAAP gross profit margin fell to 48% (vs 49% a year ago), and adjusted gross profit margin slipped to 51% (vs 52%). This suggests the company lacks the pricing power needed to offset rising material costs or tariffs, a persistent issue highlighted in prior quarters.
Weak Macro Environment Weighs on Capital Equipment
CEO Wenbin Jiang noted that growth was achieved in a 'market that continues to experience global challenges.' The modest 2.4% YoY growth in product revenue ($28.8M vs $28.1M) confirms that end-market capital equipment budgets remain tightly constrained, placing outsized pressure on Cytek's service segment to carry the growth burden.
Other KPIs
Reversing the positive adjusted EBITDA trend seen in late 2025, losses widened significantly from -$3.3M in 25Q1. This underscores severe negative operating leverage as revenue growth failed to cover the explosive rise in G&A costs.
Stable. The balance sheet remains a point of strength, increasing slightly by $0.7M from Q4 2025. This liquidity buffer is crucial as operating cash flow turns negative under the weight of litigation expenses.
Decelerating. Grew a meager 2.4% YoY, illustrating the continued reluctance of pharma, biotech, and academic customers to authorize large capital expenditures for new instruments.
Guidance
Stable. The reaffirmed guidance range implies modest full-year growth of 2% to 5% over FY25. Based on Q1's 6% growth, the guidance signals a slight deceleration in the remaining quarters, assuming no changes in current currency exchange rates. Management is baking in continued macro headwinds into this conservative outlook.
Key Questions
Bad Debt Exposure
You cited 'bad debt reserves' as a driver for the massive G&A increase. Is this exposure concentrated in a specific geography (e.g., EMEA or China) or customer segment (e.g., emerging biotech), and what is the risk of further defaults?
Litigation Expense Visibility
G&A surged 43% largely due to litigation costs. Can you provide a timeline for these legal proceedings and an estimate of when these elevated outside consulting and legal fees will normalize?
Gross Margin Trajectory
Adjusted gross margin compressed to 51%. Given the ongoing mix shift toward higher-margin service and recurring revenues (now 35% of total), why aren't we seeing a corresponding uplift in overall gross margins?